Drug Trial Radar · NCT05870748
REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1
Last checked: Nov 19, 2026Latest source record: Sep 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
600
Actual
Start
Jul 12, 2023
Primary completion
Aug 26, 2025
Study completion Aug 26, 2025
Sponsor
- Lead sponsor
- Sutro Biopharma, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- European Network of Gynaecological Oncological Trial Groups (ENGOT); Asia-Pacific Gynecologic Oncology Trials Group; GOG Foundation
- First posted
- May 23, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 2/3 study to investigate the efficacy and safety of luveltamab tazevibulin versus IC chemotherapy in women with ovarian cancer (including fallopian tube or primary peritoneal cancers) expressing FOLR1.
Conditions
- Ovarian Cancer
- Epithelial Ovarian Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Cancer
- Platinum-resistant Ovarian Cancer
Interventions
Luveltamab tazevibulinDrug
Luveltamab tazevibulin is an antibody-drug conjugate targeting FOLR1. It consists of an IgG1 antibody (SP8166) conjugated to cleavable 3-3-aminophenyl hemiasterlin drug-linkers at 4 sites. The active warhead (SC209) inhibits tubulin polymerization leading to mitotic arrest and cell death.
PegfilgrastimDrug
Pegfilgrastim or pegylated G-CSF is approved and used to decrease the incidence of infection in patients receiving myelosuppressive anti-cancer drugs. It increases the proliferation and differentiation of neutrophils.
GemcitabineDrug
Gemcitabine is a chemotherapy regimen used for treating platinum-resistant ovarian cancer. It inhibits ribonucleotide reductase and DNA polymerase, hindering tumor cell growth and promoting cell death.
PaclitaxelDrug
Paclitaxel is a chemotherapy regimen approved for treatment of previously treated ovarian cancer. It stabilizes microtubules, inhibiting tumor cell replication.
Pegylated liposomal doxorubicinDrug
Pegylated liposomal doxorubicin is a chemotherapy regimen approved for treating platinum-resistant ovarian cancer. It inhibits DNA and RNA synthesis by intercalating between base pairs, obstructing tumor cell division.
TopotecanDrug
Topotecan is a chemotherapy regimen approved for treatment of metastatic ovarian cancer after disease progression on or after initial or subsequent chemotherapy. It binds to topoisomerase I inducing DNA breaks and subsequent tumor cell apoptosis.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS)Time frame: up to 24 months
- Objective Response Rate (ORR)Time frame: up to 24 months
Locations
63 sites in 7 countries. Site status is shown where the registry gives one.
Arizona Oncology Associates, PC-Hope
Tucson, Arizona
Sutter Health
Daly City, California
Scripps Health
San Diego, California
MedStar Washington Hospital Center
Washington D.C., District of Columbia
Baptist Health South Florida (BHSF) - Miami Cancer Institute
Miami, Florida
Mount Sinai Comprehensive Cancer Center
Miami Beach, Florida
USF Research & Innovation
Tampa, Florida
Augusta University Medical Center
Augusta, Georgia
Nancy N. and J.C. Lewis Cancer & Research Pavilion at St. Joseph's/Candler
Savannah, Georgia
Sinai Hospital of Baltimore
Baltimore, Maryland
Tufts Medical Center
Boston, Massachusetts
University of Massachusetts Chan Medical School
Worcester, Massachusetts
Minnesota Oncology Hematology
Minneapolis, Minnesota
Nebraska Methodist Hospital
Omaha, Nebraska
Optimum Clinical Research Group
Albuquerque, New Mexico
NYU Langone Health
New York, New York
Good Samaritan Hospital Medical Center
West Islip, New York
Pitt County Memorial Hospital, Inc. ECU Medical Center
Greenville, North Carolina
Wake Forest Baptist Health
Winston-Salem, North Carolina
Miami Valley Hospital South
Centerville, Ohio
University of Cincinnati Medical Center
Cincinnati, Ohio
Ohio State University Center
Columbus, Ohio
Kettering Health
Kettering, Ohio
ProMedica Flower Hospital
Sylvania, Ohio
Oklahoma Cancer Specialists and Research Institute- Tulsa Cancer Center
Tulsa, Oklahoma
Oncology Associates of Oregon, PC
Eugene, Oregon
Providence Gynecologic Oncology Clinic
Portland, Oregon
Lancaster General Hospital
Lancaster, Pennsylvania
Sidney Kimmel Cancer Center, Thomas Jefferson University Hospital
Philadelphia, Pennsylvania
Vanderbilt University Medical Center
Nashville, Tennessee
Texas Oncology
Dallas, Texas
Texas Oncology-DFW
Dallas, Texas
Texas Oncology-San Antonio
San Antonio, Texas
Baylor Scott & White Medical Center - Temple (Temple Clinic)
Temple, Texas
Texas Oncology - The Woodlands
The Woodlands, Texas
Virginia Cancer Specialists
Fairfax, Virginia
Virginia Mason Medical Center - Digestive Disease Institute - Liver Center
Seattle, Washington
Chris O'Brien Lifehouse
Camperdown, New South Wales, Australia
Prince of Wales Hospital
Randwick, New South Wales, Australia
Westmead Hospital
Westmead, New South Wales, Australia
Showing 40 of 63 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.